According to BlockBeats, Qualigen Therapeutics (QLGN) experienced a significant pre-market increase of 333.8%, with shares currently priced at $12.32.
Earlier reports indicated that on September 20, Faraday Future (NASDAQ: FFAI) announced a strategic investment in Qualigen Therapeutics through a $41 million PIPE transaction. As part of this investment, Qualigen Therapeutics will rebrand as CXC10 and transition into a platform focused on cryptocurrency and Web3 business.
